Should I buy or sell NextCure stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares. View NXTC analyst ratings or view top-rated stocks .

What is NextCure's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for NextCure's stock. Their NXTC share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 265.9% from the stock's current price. View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts .

How have NXTC shares performed in 2024?

NextCure's stock was trading at $1.14 on January 1st, 2024. Since then, NXTC shares have increased by 43.9% and is now trading at $1.64. View the best growth stocks for 2024 here .

When is NextCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our NXTC earnings forecast .

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.02.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX) , ADMA Biologics (ADMA) , Matinas BioPharma (MTNB) , Bionano Genomics (BNGO) , Novan (NOVN) , Organigram (OGI) , Kadmon (KDMN) , Sorrento Therapeutics (SRNE) , Vaxart (VXRT) and DHT (DHT) .

When did NextCure IPO?

NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:NXTC

NextCure (NXTC) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free NXTC Stock Alerts

$1.64

-0.03 (-1.80%)

(As of 04:33 PM ET)

Compare

Today's Range: $1.60
▼
$1.71
50-Day Range: $1.30
▼
$2.49
52-Week Range: $0.98
▼
$2.57

Volume: 74,628 shs
Average Volume: 245,670 shs
Market Capitalization: $45.76 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get NextCure alerts:

NextCure MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 265.9% Upside
$6.00 Price Target
Short Interest: Healthy
4.71% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.79
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.65) to ($1.62) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.51 out of 5 stars

Medical Sector

80th out of 930 stocks

Pharmaceutical Preparations Industry

26th out of 422 stocks

3.5

Analyst's Opinion

Consensus Rating
NextCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
NextCure has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
4.71% of the float of NextCure has been sold short.
Short Interest Ratio / Days to Cover
NextCure has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in NextCure has recently increased by 18.35%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NextCure does not currently pay a dividend.
Dividend Growth
NextCure does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
NextCure has received a 71.38% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for NextCure is -0.79.

3.8

News and Social Media Coverage

News Sentiment
NextCure has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
Search Interest
9 people have searched for NXTC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
3 people have added NextCure to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NextCure insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.90% of the stock of NextCure is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
42.65% of the stock of NextCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for NextCure are expected to grow in the coming year, from ($1.65) to ($1.62) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NextCure is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NextCure is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NextCure has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About NextCure Stock (NASDAQ:NXTC)

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NXTC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

NXTC Stock News Headlines

April 8, 2024 | markets.businessinsider.com

Promising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy Rating

April 8, 2024 | globenewswire.com

NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 4, 2024 | globenewswire.com

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

April 2, 2024 | globenewswire.com

NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024 | finance.yahoo.com

Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?

March 23, 2024 | investorplace.com

Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich

March 22, 2024 | markets.businessinsider.com

Promising Clinical Trial Results for NextCure’s NC410 Bolster Buy Rating

April 16, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 21, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Femasys (FEMY) and NextCure (NXTC)

March 21, 2024 | marketwatch.com

NextCure to Cut 37% of Jobs, Will Narrow Focus on Drug Candidates

March 21, 2024 | bizjournals.com

Md. biopharma lays off staff, pauses manufacturing to preserve cash

March 21, 2024 | globenewswire.com

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

March 5, 2024 | globenewswire.com

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

January 18, 2024 | finance.yahoo.com

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

December 28, 2023 | benzinga.com

NextCure Stock (NASDAQ:NXTC) Dividends: History, Yield and Dates

December 25, 2023 | finance.yahoo.com

Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing

December 21, 2023 | finance.yahoo.com

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

December 15, 2023 | finance.yahoo.com

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

December 15, 2023 | markets.businessinsider.com

Buy Rating Justified by NextCure’s Promising Developments in MSS-CRC Treatment and Strategic Pipeline Shift

December 15, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: NextCure (NXTC) and Achieve Life Sciences (ACHV)

December 14, 2023 | msn.com

NextCure stock falls 20% amid program shutdown, business update

December 14, 2023 | marketwatch.com

NextCure Shares Fall 26% After Halting Development of One Drug Candidate

December 14, 2023 | finance.yahoo.com

NextCure Provides Year-End Clinical Pipeline Updates

November 20, 2023 | finance.yahoo.com

NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference

November 15, 2023 | finance.yahoo.com

NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

November 12, 2023 | morningstar.com

NextCure Inc NXTC

See More Headlines

Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:NXTC
CUSIP: N/A
CIK: 1661059
Web: www.nextcure.com
Phone: (240) 399-4900
Fax: N/A
Employees: 82
Year Founded: 2015

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $8.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +252.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-62,720,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.03%
Return on Assets: -42.59%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 16.38
Quick Ratio: 16.38

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.10 per share
Price / Book: 0.41

Miscellaneous

Outstanding Shares: 27,900,000
Free Float: 24,583,000
Market Cap: $47.43 million
Optionable: Optionable
Beta: 0.40

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Michael S. Richman MSBA (Age 63)
Co-Founder, CEO, President & Director
Comp: $713.95k
Dr. Solomon Langermann Ph.D. (Age 64)
Chief Scientific Officer
Comp: $538.62k
Dr. Han Myint FACP (Age 71)
M.D., Chief Medical Officer
Comp: $554.46k
Dr. Lieping Chen M.D. (Age 66)
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Mr. Steven P. Cobourn CPA (Age 61)
Chief Financial Officer
Comp: $313.25k
Dr. Timothy Mayer Ph.D. (Age 59)
Chief Operating Officer
Mr. Kevin G. Shaw (Age 50)
General Counsel
Ms. Stacy Rollinger
Vice President of Human Resources
Mr. Sourav Kundu Ph.D. (Age 64)
Senior Vice President of Development & Manufacturing
Dr. Sebastien Maloveste
Senior Vice President of Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NXTC Stock Analysis - Frequently Asked Questions

Should I buy or sell NextCure stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings or view top-rated stocks.
What is NextCure's stock price target for 2024?: 2 Wall Street research analysts have issued twelve-month target prices for NextCure's stock. Their NXTC share price targets range from $4.00 to $8.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 265.9% from the stock's current price.
View analysts price targets for NXTC or view top-rated stocks among Wall Street analysts.
How have NXTC shares performed in 2024?: NextCure's stock was trading at $1.14 on January 1st, 2024. Since then, NXTC shares have increased by 43.9% and is now trading at $1.64.
View the best growth stocks for 2024 here.
When is NextCure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NXTC earnings forecast.

How were NextCure's earnings last quarter?: NextCure, Inc. (NASDAQ:NXTC) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.02.
What other stocks do shareholders of NextCure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).
When did NextCure IPO?: NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.
How do I buy shares of NextCure?: Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NXTC) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

NextCure (NXTC) Stock Price, News & Analysis

NextCure MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About NextCure Stock (NASDAQ:NXTC)

NXTC Stock Price History

NXTC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

NXTC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™